Literature DB >> 22787194

Two-component cluster analysis of a large serodiagnostic database for specificity of increases of IgG antibodies against pertussis toxin in paired serum samples and of absolute values in single serum samples.

Sabine C de Greeff1, Peter Teunis, Hester E de Melker, Frits R Mooi, Daan W Notermans, Bert Elvers, Joop F P Schellekens.   

Abstract

Measuring IgG antibodies against pertussis toxin (IgG-Ptx) with an enzyme-linked immunosorbent assay (ELISA) can be used to diagnose pertussis infection; however, the cutoff points are not unanimously defined. To determine the diagnostic specificity of increases of IgG-Ptx in paired sera and of absolute values in single serum samples, we applied a two-component cluster analysis to serum samples of patients suspected for pertussis, whose sera had been submitted to a routine diagnostic laboratory between 2003 and 2009, and had been assayed with an in-house IgG-Ptx ELISA calibrated with the international FDA lot 3 IgG-Ptx reference serum. Children eligible for the acellular pertussis vaccination were excluded to avoid interference from a vaccine-induced IgG-Ptx rise. Binary distribution mixtures were fitted to the data. Receiver operating characteristic (ROC) curves were calculated for absolute values in single samples (n = 14,452) and increases in paired samples (n = 2,455). For both parameters, two subpopulations could be identified: a population with high reactivity (persons with pertussis infection) and a population with low reactivity (persons without pertussis infection). For absolute values in single samples, the area under the curve (AUC) of the ROC curve was 0.993 and the optimum cutoff (with the highest cumulative value of specificity plus sensitivity) was 67.7 IU/ml (95% confidence interval, 63.9 to 74.1; sensitivity, 96.4%; specificity, 95.7%). A previously determined diagnostic cutoff of 125 IU/ml was associated with a sensitivity of 88.1% and a specificity of 98.8%. For increases in paired sera, the AUC was 0.999 and the optimum cutoff was 3.1-fold (95% CI, 2.8 to 3.4; sensitivity, 99.6%; specificity, 99.2%). Given the methodology of this study, estimates of sensitivity probably are overrated (because pertussis patients without IgG-Ptx response are not detected), but estimates of specificities can be considered very accurate.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22787194      PMCID: PMC3428387          DOI: 10.1128/CVI.00229-12

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  31 in total

1.  Specificity and sensitivity of high levels of immunoglobulin G antibodies against pertussis toxin in a single serum sample for diagnosis of infection with Bordetella pertussis.

Authors:  H E de Melker; F G Versteegh; M A Conyn-Van Spaendonck; L H Elvers; G A Berbers; A van Der Zee; J F Schellekens
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

2.  Serological diagnosis of pertussis: evaluation of IgA against whole cell and specific Bordetella pertussis antigens as markers of recent infection.

Authors:  M Poynten; M Hanlon; L Irwig; G L Gilbert
Journal:  Epidemiol Infect       Date:  2002-04       Impact factor: 2.451

3.  European Sero-Epidemiology Network: standardisation of the assay results for pertussis.

Authors:  A Giammanco; A Chiarini; P A C Maple; N Andrews; R Pebody; N Gay; R M Olander; F Fivet-Groyne; S Baron; A Tischer; S Swidsinski; J Schellekens; E Reizenstein
Journal:  Vaccine       Date:  2003-12-08       Impact factor: 3.641

4.  Kinetics of the IgG antibody response to pertussis toxin after infection with B. pertussis.

Authors:  P F M Teunis; O G van der Heijden; H E de Melker; J F P Schellekens; F G A Versteegh; M E E Kretzschmar
Journal:  Epidemiol Infect       Date:  2002-12       Impact factor: 2.451

5.  Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: the APERT Study.

Authors:  Thuan Le; James D Cherry; Swei-Ju Chang; Maria Deloria Knoll; Martin L Lee; Steve Barenkamp; David Bernstein; Robert Edelman; Kathryn M Edwards; David Greenberg; Wendy Keitel; John Treanor; Joel I Ward
Journal:  J Infect Dis       Date:  2004-07-07       Impact factor: 5.226

6.  A clinical validation of Bordetella pertussis and Bordetella parapertussis polymerase chain reaction: comparison with culture and serology using samples from patients with suspected whooping cough from a highly immunized population.

Authors:  A van der Zee; C Agterberg; M Peeters; F Mooi; J Schellekens
Journal:  J Infect Dis       Date:  1996-07       Impact factor: 5.226

7.  Serum IgA antibody to Bordetella pertussis as an indicator of infection.

Authors:  J Nagel; E J Poot-Scholtens
Journal:  J Med Microbiol       Date:  1983-11       Impact factor: 2.472

8.  Different IgG-subclass distributions after whole-cell and acellular pertussis infant primary vaccinations in healthy and pertussis infected children.

Authors:  Lotte H Hendrikx; Rose-Minke Schure; Kemal Oztürk; Lia G H de Rond; S C de Greeff; Elisabeth A M Sanders; Guy A M Berbers; Anne-Marie Buisman
Journal:  Vaccine       Date:  2011-07-29       Impact factor: 3.641

9.  Pertussis in Massachusetts, 1981-1991: incidence, serologic diagnosis, and vaccine effectiveness.

Authors:  C D Marchant; A M Loughlin; S M Lett; C W Todd; L H Wetterlow; R Bicchieri; S Higham; P Etkind; E Silva; G R Siber
Journal:  J Infect Dis       Date:  1994-06       Impact factor: 5.226

10.  Improved serodiagnosis of whooping cough caused by Bordetella pertussis by determination of IgG anti-LPF antibody levels.

Authors:  J Nagel; S de Graaf; D Schijf-Evers
Journal:  Dev Biol Stand       Date:  1985
View more
  7 in total

1.  Study of a Cohort of 1,886 Persons To Determine Changes in Antibody Reactivity to Borrelia burgdorferi 3 Months after a Tick Bite.

Authors:  Ram B Dessau; Linda Fryland; Peter Wilhelmsson; Christina Ekerfelt; Dag Nyman; Pia Forsberg; Per-Eric Lindgren
Journal:  Clin Vaccine Immunol       Date:  2015-05-20

Review 2.  Laboratory Diagnosis of Pertussis.

Authors:  Anneke van der Zee; Joop F P Schellekens; Frits R Mooi
Journal:  Clin Microbiol Rev       Date:  2015-10       Impact factor: 26.132

3.  The burden of disease and health care use among pertussis cases in school aged children and adults in England and Wales; a patient survey.

Authors:  Albert Jan van Hoek; Helen Campbell; Nick Andrews; Mariza Vasconcelos; Gayatri Amirthalingam; Elizabeth Miller
Journal:  PLoS One       Date:  2014-11-25       Impact factor: 3.240

4.  Seroepidemiology of pertussis in a cross-sectional study of an adult general population in Denmark.

Authors:  P F Rønn; T Dalby; J Simonsen; C S Jørgensen; A Linneberg; K A Krogfelt
Journal:  Epidemiol Infect       Date:  2013-10-09       Impact factor: 4.434

5.  Seroprevalence of pertussis in the Gambia: evidence for continued circulation of bordetella pertussis despite high vaccination rates.

Authors:  Susana Scott; Marianne van der Sande; Tisbeh Faye-Joof; Maimuna Mendy; Bakary Sanneh; Fatou Barry Jallow; Hester de Melker; Fiona van der Klis; Pieter van Gageldonk; Frits Mooi; Beate Kampmann
Journal:  Pediatr Infect Dis J       Date:  2015-04       Impact factor: 2.129

6.  The Use of Innovative Two-Component Cluster Analysis and Serodiagnostic Cut-Off Methods to Estimate Prevalence of Pertussis Reinfections.

Authors:  Inonge van Twillert; Axel A Bonačić Marinović; Jacqueline A M van Gaans-van den Brink; Betsy Kuipers; Guy A M Berbers; Nicoline A T van der Maas; Theo J M Verheij; Florens G A Versteegh; Peter F M Teunis; Cécile A C M van Els
Journal:  PLoS One       Date:  2016-02-05       Impact factor: 3.240

7.  In silico identification and modification of T cell epitopes in pertussis antigens associated with tolerance.

Authors:  Corine Kruiswijk; Guilhem Richard; Merijn L M Salverda; Pooja Hindocha; William D Martin; Anne S De Groot; Elly Van Riet
Journal:  Hum Vaccin Immunother       Date:  2020-01-17       Impact factor: 3.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.